Benzofuran RCs & Entactogens: 6-APB, 5-APB, 5-MAPB and Related Compounds

Benzofuran RCs & Entactogens

Quick answer

Benzofuran RCs such as 6-APB, 5-APB and 5-MAPB are stimulant/entactogen NPS often compared with MDMA.

That comparison is useful chemically and phenomenologically, but it can hide major evidence gaps.

The published human literature is far smaller than the internet discussion volume.

Pharmacology

Benzofurans can increase monoamine signaling involving:

• serotonin;
• dopamine;
• norepinephrine.

That creates a mixture of stimulant, empathogenic and sometimes psychedelic-like effects.

It also creates familiar monoaminergic toxicity concerns.

Severe effects reported in the literature

Published cases include:

• agitation;
• paranoia or psychosis;
• tachycardia;
• hypertension;
• hyperthermia;
• tremor;
• clonus;
• hallucinations;
• convulsions;
• reduced consciousness.

6-APB

6-APB has analytically confirmed poisoning reports and has been detected in multi-drug fatalities.

See the dedicated 6-APB evidence review.

5-MAPB

5-MAPB has a published analytically confirmed toxicity case involving cardiovascular, neurologic and serotonin-like findings.

It deserves its own future profile rather than being treated as interchangeable with 6-APB.

Why MDMA equivalence is uncertain

A claim that one RC is “basically MDMA but longer,” “cleaner,” or “less neurotoxic” is not established by subjective similarity.

Differences in:

• transporter activity;
• receptor activity;
• metabolism;
• duration;
• impurity profiles;
• tablet/powder concentration

can materially change risk.

Additional individual profiles

• 5-APB
• 6-MAPB

Bottom line

Benzofuran entactogens sit in a dangerous evidence gap: familiar enough to invite MDMA comparisons, but less studied and often unregulated.

The appropriate interpretation is not that they are automatically more dangerous than MDMA in every circumstance—it is that the safety margin is less well characterized.

Why the human evidence for Benzofuran RCs & Entactogens needs careful interpretation

A useful review of Benzofuran RCs & Entactogens has to separate confirmed exposure from assumed exposure. Analytical identification can establish that a compound was present, while a clinical case describes what happened to one person under a specific set of circumstances. Neither alone tells us how common an adverse effect is. Laboratory receptor or animal studies add mechanistic detail, but they do not supply a human safety threshold. Keeping those layers separate prevents a thin evidence base from turning into an invented potency chart.

Why product identity matters as much as the drug name

Entactogen and psychedelic RCs can be sold as powders, crystals, capsules, tablets, blotters, or products marketed under a more familiar name. Visual appearance cannot distinguish Benzofuran RCs & Entactogens from a related analogue, and a seller's label does not establish purity or concentration. Analytical misidentification can also happen when laboratories do not have the right reference material or include the relevant compound in a screening panel.

That uncertainty changes harm interpretation. If an exposure produces unexpectedly intense stimulation, prolonged confusion, severe overheating, or loss of consciousness, assuming the product is “just Benzofuran RCs & Entactogens” can delay recognition of a substitution or mixture.

Red flags that need medical attention

Severe hyperthermia, seizure, collapse, chest pain, very abnormal heart rate or blood pressure, persistent unconsciousness, extreme agitation, or rapidly worsening confusion should not be written off as an expected entactogen or psychedelic effect. These findings may reflect direct toxicity, an interaction, dehydration/overheating, a substituted compound, or another medical emergency.

Serotonergic or stimulant-like drugs can become harder to interpret when combined with MAO inhibitors, other entactogens, stimulant cathinones, or multiple serotonergic substances. A missing compound-specific interaction trial is an evidence gap, not a guarantee of safety.

What is still missing

For Benzofuran RCs & Entactogens, important gaps can include controlled human pharmacokinetics, uncommon adverse-event frequency, interaction studies, active-metabolite relevance, and longer-term outcomes. Case reports can establish that a problem is possible; they cannot tell us how often it happens among all users.

Future updates should become more specific only when better human evidence supports that precision. Until then, the evidence grade remains conservative and this page avoids recreational dose ranges or “equivalent” conversions.